Gilead Sciences, Inc. (GILD)
| Previous close | 68.81 |
| Open | 69.36 |
| Bid | 68.85 x 1000 |
| Ask | 68.93 x 800 |
| Day's range | 68.82 - 69.73 |
| 52-week range | 60.89 - 85.97 |
| Volume | 2,439,870 |
| Avg. volume | 9,953,084 |
| Market cap | 86.414B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.20 |
| Earnings date | 22 Oct 2020 - 26 Oct 2020 |
| Forward dividend & yield | 2.72 (3.94%) |
| Ex-dividend date | 14 Sep 2020 |
| 1y target est | 80.17 |
- Business Wire
Diodes Incorporated Reports Second Quarter 2020 Financial Results
Diodes Incorporated (Nasdaq: DIOD) today reported its financial results for the second quarter ended June 30, 2020.
- Motley Fool
Is Gilead Sciences a Buy After Its Disappointing Q2 Results?
Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.
- Motley Fool
Better Buy: Gilead Sciences vs. Pfizer
Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE) are two of the most competent pharmaceutical companies in the industry. Recently, Gilead has been in the headlines thanks to its much-discussed antiviral drug remdesivir, which appears to be somewhat beneficial for treating coronavirus infections in certain patient populations. It helps that Gilead was an attractive company well before the pandemic, with normalized trailing 12-month diluted earnings per share (EPS) of $3.90 in contrast with Pfizer's $1.98 and a robust profit margin of 21.8%, slightly trailing Pfizer's 28.8%.
